EP0784482A2 - Methods for inhibiting antigen specific t cell responses - Google Patents
Methods for inhibiting antigen specific t cell responsesInfo
- Publication number
- EP0784482A2 EP0784482A2 EP95922279A EP95922279A EP0784482A2 EP 0784482 A2 EP0784482 A2 EP 0784482A2 EP 95922279 A EP95922279 A EP 95922279A EP 95922279 A EP95922279 A EP 95922279A EP 0784482 A2 EP0784482 A2 EP 0784482A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibody
- cell
- cells
- agent
- recipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25526794A | 1994-06-07 | 1994-06-07 | |
US255267 | 1994-06-07 | ||
US47269795A | 1995-06-06 | 1995-06-06 | |
US472697 | 1995-06-06 | ||
PCT/US1995/007351 WO1995034320A2 (en) | 1994-06-07 | 1995-06-07 | Methods for inhibiting antigen specific t cell responses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0784482A2 true EP0784482A2 (en) | 1997-07-23 |
Family
ID=26944578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95922279A Withdrawn EP0784482A2 (en) | 1994-06-07 | 1995-06-07 | Methods for inhibiting antigen specific t cell responses |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0784482A2 (ja) |
JP (1) | JPH10501815A (ja) |
AU (1) | AU2701895A (ja) |
CA (1) | CA2191733A1 (ja) |
WO (1) | WO1995034320A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014865A1 (en) * | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
ATE292689T1 (de) * | 1995-05-04 | 2005-04-15 | Us Navy | Verbesserte verfahren zur transfektion der t- zellen |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
DE69723230T2 (de) * | 1996-01-17 | 2004-05-27 | Imperial College Innovations Ltd. | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
ES2133085B1 (es) * | 1996-12-30 | 2000-04-01 | Hospital Universitario Virgen | Metodo de analisis del rechazo agudo en trasplante ortotopico de higado mediante la determinacion de la intensidad de expresion de las moleculas coestimuladoras (cd28, ctla-4, cd80 y cd86) en la superficie de linfocitos de sangre periferica por citometria de flujo. |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7235653B2 (en) | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
CA2291338A1 (en) * | 1997-06-11 | 1998-12-17 | Wisconsin Alumni Research Foundation | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
JP2002502824A (ja) * | 1998-02-04 | 2002-01-29 | ザ・ジェネラル・ホスピタル・コーポレイション | 同種移植における補刺激遮断および混合キメラ現象 |
US6841347B1 (en) | 1998-02-05 | 2005-01-11 | The General Hospital Corporation | In vivo construction of DNA libraries |
EP1074268B1 (en) | 1998-03-17 | 2008-01-16 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
WO2000014116A1 (en) * | 1998-09-04 | 2000-03-16 | Baylor College Of Medicine | T cell peptides as therapeutics for immune-related disease |
AU768547B2 (en) * | 1999-01-08 | 2003-12-18 | Wisconsin Alumni Research Foundation | Methods of prolonging transplant survival using immunotoxins and costimulation blockade of CD154 and CD28 |
CA2362592A1 (en) | 1999-02-12 | 2000-08-17 | Genetics Institute, Inc. | Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
US6541608B1 (en) | 1999-02-23 | 2003-04-01 | Baylor College Of Medicine | T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection |
RU2251552C2 (ru) | 1999-02-23 | 2005-05-10 | Бейлор Колледж Оф Медисин | Vβ-Dβ-Jβ ОЛИГОНУКЛЕОТИД Т-КЛЕТОЧНОГО РЕЦЕПТОРА, ПАРА ПРАЙМЕРОВ, ОЛИГОНУКЛЕОТИДНЫЙ ЗОНД, СПОСОБ ОБНАРУЖЕНИЯ КЛОНА MBP83-99Vβ13.1 Т-КЛЕТОК, ЭКСПРЕССИРУЮЩИХ МОТИВ LGRAGLTY Т-КЛЕТОЧНОГО РЕЦЕПТОРА, НАБОР, СПОСОБ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ И СПОСОБ ЕГО МОНИТОРИНГА |
PL200134B1 (pl) | 1999-05-07 | 2008-12-31 | Genentech Inc | Zastosowanie przeciwciała anty-CD20 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001068134A2 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
TWI322153B (en) | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
KR100824824B1 (ko) | 2000-10-25 | 2008-04-23 | 추가이 세이야쿠 가부시키가이샤 | 아이엘-6 안타고니스트를 유효 성분으로서 함유하는건선의 예방 또는 치료제 |
PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
US7897582B2 (en) | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7960355B2 (en) | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
CA2934682C (en) * | 2004-03-22 | 2021-12-07 | Mesoblast International Sarl | Mesenchymal stem cells and uses therefor |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
CA2893204C (en) | 2006-01-13 | 2016-11-29 | Alla Danilkovitch | Mesenchymal stem cells expressing tnf-.alpha. receptors |
EP2624846A2 (en) | 2010-10-08 | 2013-08-14 | Osiris Therapeutics, Inc. | Nanoparticle-loaded cells |
WO2020127509A1 (en) * | 2018-12-18 | 2020-06-25 | Catapult Therapeutics B.V. | The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd) |
WO2020172391A1 (en) * | 2019-02-22 | 2020-08-27 | The Children's Medical Center | Methods and compositions relating to the treatment of gvhd |
KR20220131293A (ko) | 2020-01-24 | 2022-09-27 | 화이자 인코포레이티드 | 항-e-셀렉틴 항체, 조성물 및 사용 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995003408A1 (en) * | 1993-07-26 | 1995-02-02 | Dana-Farber Cancer Institute | B7-2: ctl a4/cd 28 counter receptor |
-
1995
- 1995-06-07 AU AU27018/95A patent/AU2701895A/en not_active Abandoned
- 1995-06-07 CA CA002191733A patent/CA2191733A1/en not_active Abandoned
- 1995-06-07 JP JP8502351A patent/JPH10501815A/ja not_active Ceased
- 1995-06-07 WO PCT/US1995/007351 patent/WO1995034320A2/en not_active Application Discontinuation
- 1995-06-07 EP EP95922279A patent/EP0784482A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9534320A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2701895A (en) | 1996-01-05 |
WO1995034320A2 (en) | 1995-12-21 |
WO1995034320A3 (en) | 1996-01-18 |
JPH10501815A (ja) | 1998-02-17 |
CA2191733A1 (en) | 1995-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0784482A2 (en) | Methods for inhibiting antigen specific t cell responses | |
Blazar et al. | In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice | |
US20200115457A1 (en) | Chimeric receptors and methods of use thereof | |
Blazar et al. | Infusion of anti-B7. 1 (CD80) and anti-B7. 2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. | |
AU684461B2 (en) | CD28 pathway immunoregulation | |
Blazar et al. | Coblockade of the LFA1: ICAM and CD28/CTLA4: B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts | |
US11667723B2 (en) | Lymphocytes-antigen presenting cells co-stimulators and uses thereof | |
Haspot et al. | Anti‐CD28 Antibody‐Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR− Class II− B7+ Regulatory Cells | |
US20080305092A1 (en) | Methods of treating autoimmune disease via CTLA-4IG | |
JPH09501824A (ja) | モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質 | |
JP2007126481A (ja) | T細胞の不応答性を調節する方法 | |
US5843425A (en) | Transplantation and graft-versus-host-disease | |
US20120269806A1 (en) | Methods of inducing tolerance | |
WO1996014865A1 (en) | Methods for inhibiting graft versus host disease in bone marrow transplantation | |
US20040185046A1 (en) | Methods of treating autoimmune disease via CTLA-4Ig | |
US6576236B1 (en) | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain | |
US20030170239A1 (en) | Immunotherapeutic method to prevent islet cell rejection | |
Page et al. | Lymphodepletional strategies in transplantation | |
Zhai et al. | The CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8+ T cells by skin grafts via direct antigen presentation | |
US20060233795A1 (en) | Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells | |
Kumamoto et al. | Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice | |
JP2003534283A (ja) | 天然で誘導されたかまたは人工的に誘導された免疫抑制後にt細胞免疫サーベイランスを回復もしくは増強するための方法 | |
AU748561B2 (en) | Methods for inhibiting antigen specific T cell responses | |
WO1997017360A2 (en) | Methods for modulating t cell responses by manipulating a common cytokine receptor gamma chain | |
EP2729497B1 (en) | An antibody inducing antigen-specific t cell tolerance and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970102 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020326 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050923 |